Chenxu Jia, Qingtao Meng, Mingna Huo, Fengping Zhang, Jian Han
{"title":"The Multitalented Marvels: Exploring the Versatile Potential of Natural Products in Osteosarcoma Treatment.","authors":"Chenxu Jia, Qingtao Meng, Mingna Huo, Fengping Zhang, Jian Han","doi":"10.1177/11769351261474027","DOIUrl":null,"url":null,"abstract":"<p><p>Osteosarcoma (OS) is a malignant neoplasm arising from bone tissue. The OS exhibited a significant degree of heterogeneity, with a high incidence of local invasion and a high rate of metastasis. Approximately 25% of those diagnosed with OS present with metastases, with the lungs being the most prevalent site, followed by the bones or lymph nodes. The 5-year survival rate for patients with OS with lung metastasis is only 10% to 30%. Adjuvant chemotherapy regimens significantly enhanced the 5-year survival rate in patients diagnosed with non-metastatic OS. However, the same regimens did not provide a substantial improvement in survival for patients with OS who had acquired lung metastasis or had recurrence. Moreover, the extensive use of chemotherapy medications often results in the development of resistance to chemotherapy in patients with OS, which frequently culminates in treatment ineffectiveness. Natural products (NPs) are significant reservoirs of anti-cancer medications. Preclinical investigations have shown that certain NPs had substantial promise for treating OS. However, there is currently a lack of a comprehensive overview of the use of NPs in OS treatment. In this review, we provide a comprehensive overview of the NPs, which include polyphenols, alkaloids, and terpenoids, that have the potential to be effective in the treatment of OS.</p>","PeriodicalId":35418,"journal":{"name":"Cancer Informatics","volume":"25 ","pages":"11769351261474027"},"PeriodicalIF":2.1000,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13428158/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Informatics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11769351261474027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MATHEMATICAL & COMPUTATIONAL BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Osteosarcoma (OS) is a malignant neoplasm arising from bone tissue. The OS exhibited a significant degree of heterogeneity, with a high incidence of local invasion and a high rate of metastasis. Approximately 25% of those diagnosed with OS present with metastases, with the lungs being the most prevalent site, followed by the bones or lymph nodes. The 5-year survival rate for patients with OS with lung metastasis is only 10% to 30%. Adjuvant chemotherapy regimens significantly enhanced the 5-year survival rate in patients diagnosed with non-metastatic OS. However, the same regimens did not provide a substantial improvement in survival for patients with OS who had acquired lung metastasis or had recurrence. Moreover, the extensive use of chemotherapy medications often results in the development of resistance to chemotherapy in patients with OS, which frequently culminates in treatment ineffectiveness. Natural products (NPs) are significant reservoirs of anti-cancer medications. Preclinical investigations have shown that certain NPs had substantial promise for treating OS. However, there is currently a lack of a comprehensive overview of the use of NPs in OS treatment. In this review, we provide a comprehensive overview of the NPs, which include polyphenols, alkaloids, and terpenoids, that have the potential to be effective in the treatment of OS.
期刊介绍:
The field of cancer research relies on advances in many other disciplines, including omics technology, mass spectrometry, radio imaging, computer science, and biostatistics. Cancer Informatics provides open access to peer-reviewed high-quality manuscripts reporting bioinformatics analysis of molecular genetics and/or clinical data pertaining to cancer, emphasizing the use of machine learning, artificial intelligence, statistical algorithms, advanced imaging techniques, data visualization, and high-throughput technologies. As the leading journal dedicated exclusively to the report of the use of computational methods in cancer research and practice, Cancer Informatics leverages methodological improvements in systems biology, genomics, proteomics, metabolomics, and molecular biochemistry into the fields of cancer detection, treatment, classification, risk-prediction, prevention, outcome, and modeling.